Kornimate/medical-research-clean huggingface dataset:
effectiveness of group acceptance and commitment therapy in treating acute stroke patients with depression

Conditions: Acute Stroke Patients With Depression

Summary: the goal of this clinical trial is to discover the effectiveness of group-based acceptance and commitment therapy (act) in treating depression for acute stroke patients. the main question\[s\] it aims to answer are: * group-based act (g-act) could significantly reduce the depressive symptoms in patients with acute stroke, * the interventional efficacy could be maintained at 3-month follow-up * similar benefits would be observed for quality of life (qol), sleep quality, psychological flexibility, cognitive fusion, and confidence. the patients included to the control group received usual care support in hospital, and the patients included to the intervention group received g-act and usual care support. the g-act treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.


Eligibility criteria:
inclusion criteria: 1. primary diagnosis of acute stroke, the last onset occurred within 2 weeks 2. being over 18 years old 3. scoring at least 8 on the hamd scale 4. be conscious and able to communicate effectively with researchers 5. primary school education level or above, 6) having signed informed consent. exclusion criteria: 1. having a history of mental illness (such as bipolar disorder) or dementia, using psychiatric drugs or sedatives within 6 months, or currently using antidepressants 2. a diagnosis of cognitive impairment 3. receiving a psychological therapy in the previous three months, or currently experiencing severe psychotic symptoms 4. a history of drug abuse or dependence
efficacy study of hydrocephalus surgery by methods of neuroelectrophysiology

Conditions: Hydrocephalus

Summary: the symptoms of hydrocephalus containing consciousness condition with muscle tone in some patients will be relieved, after the cerebrospinal fluid release test is carried out. neuroelectrophysiology in patients with disorders of consciousness of post-traumatic hydrocephalus (pth) can establish the association with consciousness and muscle tone to a certain extent, and predict the shunt effect of pth with disorders of consciousness.


Eligibility criteria:
inclusion criteria: patients with disorder of consciousness in traumatic brain injury. the presence of hydrocephalus through image examination. exclusion criteria: patients who cannot tolerate shunt surgery. sedation maintained by greater than 0.15mg/kg/hour of midazolam or the infusion dose of propofol higher than 4mg/kg/hour. patients who are participating in drug research or other clinical trials.

Keywords: neuroelectrophysiology hydrocephalus disorder of consciousness
trial of osteoporosis intervention strategies in hip fracture patients

Conditions: Osteoporosis

Summary: the objective of this study is to determine if an intervention with a fracture manager to arrange bone densitometry after a hip fracture is more effective in diagnosing and treating osteoporosis when compared to "usual care". "usual care" consists of no intervention to arrange bone mineral density (bmd) testing or therapy other than what normally occurs in the community. the investigators postulate that a fracture manager will be more effective in getting bmd done and in starting appropriate therapy.

all hip fracture patients in the edmonton area will be screened for eligibility (mini-mental status \>20, not on active osteoporosis pharmacologic therapy). all patients will have informed consent obtained. patients will be randomized to 2 groups: * group 1: active intervention. the fracture manager will arrange for bone densitometry (dexa) to be done 3-6 months after the fracture. if the patient meets standard criteria for osteoporosis, therapy with a bisphosphonate (alendronate or risedronate) will be instituted by the study physicians. * group 2: usual care. patients will receive basic information about calcium and vitamin d and osteoporosis and told to follow up with their family doctor. at 6 months, patients will be contacted to determine if they have had a bmd done or started on active (drug) osteoporosis therapy. if not, the fracture manager will arrange the bmd and if appropriate therapy will be started by the study physicians. all patients will be followed for 1 year. the primary endpoints are the number of patients who get a bmd and the number who are started on active osteoporosis therapy.

Eligibility criteria:
inclusion criteria: * ages 50 or over; males or females. * reside in the community or have access to bone densitometry * hip fracture * patient can consent or proxy consent available * no contraindications to bisphosphonates exclusion criteria: * patient refuses consent process * already receiving active drug therapy for osteoporosis other than calcium and vitamin d * dementia or delirium * pathological fracture * chronic corticosteroid therapy

Keywords: osteoporosis hip fracture
stomp early years: a pilot rct of an intensive, family-centred, home visiting intervention for young children with severe obesity

Conditions: Child Obesity

Summary: this internal pilot study will determine whether a highly promising primary care based intervention that combines group based parenting skills training and public health nurse home visits with a focus on healthy nutrition, activity and sleep, will lead to improved weight status in 1 to 5 year old children with severe obesity. children with severe obesity will be identified through the obesity management clinical program at the hospital for sick children called stomp (sickkids team obesity management program). the stomp early years program is a unique and intensive, paediatric obesity management program designed for 1 to 5 year-olds with severe obesity and their families. families who participate in this study will be randomly assigned (having an equal chance of being in either group) to one of the two study groups that will run for 6 months: group a: ten weeks of group parenting education sessions with 2-4 public health nurse home visits and four one-on-one check-ins with an interdisciplinary team at stomp. group b: wait listed to receive parenting education sessions; receive one-on-one checks with an interdisciplinary team at stomp. in addition to the measures collected as part of stomp, families will complete the following questionnaires before the start of the trial, and after 6 months: parenting scale, parenting stress index, depression, anxiety, and stress scale (dass-21), cost questionnaire, and children's behaviour questionnaire (cbq).


Eligibility criteria:
inclusion criteria: * children with obesity and severe obesity (bmi ≥97th percentile) and at least one parent (primary caregiver), and families who are fluent in english (written and oral) will be eligible to participate. exclusion criteria: * children with diagnosed prader-willi syndrome; severe developmental delay; and families who reside beyond the toronto public health catchment area for home visiting.

Keywords: parenting home visiting childhood obesity treatment
voiding class study for symptom reduction and quality of life in children with luts

Conditions: Lower Urinary Tract Symptoms

Summary: lower urinary tract dysfunction (lutd) is a common pathology within children and shows a wide spectrum of lower urinary tract symptoms (luts). these symptoms have a significant impact on a child's well-being. for the treatment of luts in children urotherapy, a non-medicamentous form of therapy, is implemented as standard therapy. it can be described as a bladder re-education and rehabilitation programme where the participants are informed on the anatomy and physiology of the normal and pathological urinary system. urotherapy has been offered as individual therapy for a long time but is now also offered as group therapy (the voiding school). this is, as compared to the individual therapy, more cost-effective and gives the participants the feeling not to be alone in the situation. the effectiveness of the individual therapy for children with lutd has already been determined, however little research has been done on the effectiveness of urotherapy in group (the voiding class). the present study wants to investigate the effect of the group therapy on the symptoms and quality of life of children with lutd.

the current study is a prospective cohort-study in which information of the impact of the voiding class on the symptoms and well-being of the children is obtained through two questionnaires, respectively the vancouver symptom score for dysfunctional elimination syndrome (vssdes) and the paediatric incontinence questionnaire (pinq). participants of this study are as well asked to complete drinking and voiding charts and nocturnal diaries. these questionnaires and documents are filled in before and after the voiding class. the collected data will be further analysed statistically trough statistical package for the social sciences (spps), to determine significant improvements in symptoms and quality of life.

Eligibility criteria:
inclusion criteria: * children (5-12 years old) * children with luts * children who follow voiding school, with or without previously failed training exclusion criteria: * children \>12 years ol and \<5 years old * children who suffer from solely faecal problems without lower urinary tract symptoms * children who are currently following a different kind of therapy concerning the luts, than vc * children with neurological disorders or anatomical variations of the bladder * children who underwent surgical intervention of the bladder

Keywords: voiding class quality of life children
morbidity in patients with hypertension and obstructive sleep apnea

Conditions: Hypertension; Sleep Apnea, Obstructive

Summary: morpheos is a multicenter, randomized, unblinded study, for patients diagnosed with uncontrolled hypertension and at least one antihypertensive medication. those patients with significant sleep apnea wil be randomized to cpap or nasal strips for 6 months.


Eligibility criteria:
inclusion criteria: * systolic blood pressure ≥140 mm hg or diastolic blood pressure ≥ 90 mm hg * current treatment with at least 1 antihypertensive drug exclusion criteria: * age \ 65 years * bmi ≥ 40 kg/m2 * heart failure, ef \< 45%, acute myocardial infarction, stroke, significant valvular dysfunction * chronic renal failure (serum creatinine \> 2 mg/dl) * use of cocaine, amphetamines, alcohol, illicit drugs * use of sympathomimetics (decongestants, appetite suppressants) * use of oral contraceptives and chronic use of nsaids * pregnancy * secondary causes of hypertension (other than sleep apnea)

Keywords: continuous positive airway pressure hypertension sleep apnea
gotha - the early arthritis and psoriasis study of region västra götaland, sweden

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Arthritis; Psoriasis; Cardiovascular Diseases; Obesity; Lung Diseases

Summary: götha- the early arthritis and psoriasis study of region västra götaland, sweden - is a longitudinal observational study, which will prospectively and in parallel follow patients with newly diagnosed rheumatoid arthritis (ra, n=1000), psoriatic arthritis (psa, n=500) and undifferentiated arthritis (n=100), together with patients with psoriasis (n=500). the study will also recruit healthy controls from the general population (n=3000). the aims of the study are to define predictors for disease course and severity, treatment response, comorbidities, health related quality of life (hrqol) and health economy. the study is a collaboration between the department of rheumatology and the department of dermatology at sahlgrenska university hospital in gothenburg, and the departments of rheumatology at the hospitals of alingsås, borås, uddevalla and skövde, in the west of sweden. all patients with newly diagnosed ra, psa and undifferentiated arthritis at the rheumatology centers are eligible for inclusion. patients with psoriasis will be recruited from the department of dermatology at sahlgrenska university hospital. the patients will be examined at baseline and at one, three, five and ten years. the assessments will include physical examination with evaluation of joints, entheses and skin and validated questionnaires regarding medical history, comorbidities, lifestyle, disease activity, bodily function, socioeconomic factors and hrqol. blood samples will be collected. the patients with arthritis will also undergo radiography of the lung, hands and feet, and cone beam computed tomography (cbct) of hands and feet.


Eligibility criteria:
inclusion criteria: * patients with rheumatoid arthritis (ra) meeting the classification criteria of american college of rheumatology (acr) and/or european league against rheumatism (eular) från 2010 * patients with psoriatic arthritis (psa) meeting the classification criteria of classification for psoriatic arthritis (caspar) psa * patients with undifferentiated arthritis defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease * patients with psoriasis diagnosed at a dermatology department. the patients should not have any history of joint complaints with a duration of more than 6 weeks * general population controls, matched for age, sex and residence of living to the included patients. exclusion criteria: * inability to follow study protocol * swedish language difficulties * having other concomitant rheumatic diagnose (sjögrens syndrome is not an exclusion criteria)
open-label long-term safety and efficacy study of fixed dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in subjects with moderate to severe essential hypertension

Conditions: Hypertension

Summary: this study examines the long term safety and efficacy of the fixed dose combination bay98-7106 (nifedipine plus candesartan primarily at the highest dose in development) in patients with moderate to severe hypertension. patients meeting the entry criteria, will receive the fixed dose combination for 28 weeks, including 8 weeks with stepwise dose increase up to the high target dose. the first 200 subjects completing 28 weeks will continue treatment for additional 24 weeks (52 weeks in total). subjects who do not tolerate an increased dose will be treated at their highest tolerable dose.


Eligibility criteria:
inclusion criteria: * subjects must have moderate to severe essential hypertension (grade 2 or grade 3, who classifications). at visit 1, subjects not treated with antihypertensive medications are to have mssbp of \>/= 160 mmhg and \ /= 160 mmhg and \<200 mmhg after wash out. * women of childbearing potential and men must agree to use adequate contraception other than hormonal contraceptives when sexually active exclusion criteria: * mean seated systolic blood pressure \>/= 200 mmhg and/or mean seated diastolic blood pressure \>/= 120 mm/hg * mean seated diastolic blood pressure \< 60 mm/hg * differences greater than 20 mmhg for systolic blood pressure and 10 mmhg for diastolic blood pressure are present on 3 consecutive blood pressure readings at visit 0 * any history of hypertensive emergency * evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma, hyperaldosteronism, etc. * cerebrovascular ischemic event (stroke, transient ischemic attack \[tia\])within the previous 12 months * history of intracerebral hemorrhage or subarachnoid hemorrhage * history of hypertensive retinopathy - known keith-wagener grade iii or iv * any history of heart failure, new york heart association (nyha) classification iii or iv * severe coronary heart disease as manifest by a history of myocardial infarction or unstable angina in the last 6 months prior to visit 0 * type 1 diabetes mellitus (dm) or poorly controlled type 2 dm as evidenced by hba1c of greater than 9% on visit 0. * hyperkalemia: potassium above the upper limit of normal in the laboratory range

Keywords: drug combination nifedipine gits candesartan cilexetil hypertension combination therapy
nutritional supplements in improving quality of life during first-line chemotherapy in patients with metastatic gynecological cancer

Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer

Summary: rationale: learning about the effect of nutritional supplements on quality of life in patients receiving chemotherapy for cancer may help doctors plan the best treatment. purpose: this randomized phase ii trial is studying nutritional supplements to see how well they work in improving quality of life during first-line chemotherapy in patients with metastatic gynecologic cancer.

objectives: primary * measure quality of life (qlq-c30) at week 18 in patients with metastatic gynecological cancer receiving systematic nutritional supplements during first-line chemotherapy. secondary * study the maintenance or improvement of intake and nutritional status. * study the quality of life during chemotherapy. * evaluate tolerance and compliance to treatment with nutritional supplements. * evaluate the feasibility of and the tolerance to chemotherapy. * measure the overall survival over 18 weeks. * analyze the cost-effectiveness of different strategies of nutritional care. outline: patients are randomized to 1 of 3 treatment arms. * arm i: patients are monitored via standard follow-up assessments every 3 weeks. * arm ii: patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks. * arm iii: patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.

Eligibility criteria:
disease characteristics: * histologically confirmed gynecological cancer * currently receiving first-line chemotherapy for metastatic disease patient characteristics: * who performance status (ps) 0-2 or karnofsky ps 70-100% * not pregnant or nursing * intake \< 75% of theoretical need * weight loss ≥ 5% within the past 6 months * no patients with dementia or altered mental status * no psychological, familial, social, or geographic situations that preclude clinical follow up prior concurrent therapy: * see disease characteristics * no concurrent radiotherapy

Keywords: stage iva cervical cancer stage ivb cervical cancer fallopian tube cancer stage iv ovarian epithelial cancer stage iv ovarian germ cell tumor ovarian sarcoma ovarian stromal cancer stage iv endometrial carcinoma stage iv uterine sarcoma stage iva vaginal cancer stage ivb vaginal cancer stage iv vulvar cancer
zero heat flux temp monitor on discharge hypothermia among trauma patients (ruzit trial)

Conditions: Hypothermia; Trauma; Temperature Change, Body

Summary: hypothermia amongst trauma patients is a persistent problem that increases the relative risk of transfusion as well as morbidity and mortality. the investigators propose to conduct a single-centered randomized controlled trial to determine if the use of a zero-heat flux (zhf) temperature monitor can reduce the incidence of hypothermia amongst trauma patients discharged from the trauma bay (tb). all eligible trauma patients will be randomized to either a standard of care group or an active temperature monitoring group. in the active temperature monitoring group, a zhf monitor will be placed on respective trauma patients to continuously record their temperatures after they enter the tb at a large tertiary trauma centre, sunnybrook health sciences centre (shsc), in toronto, on. the investigators will determine if early continuous temperature monitoring can reduce the incidence of hypothermia upon discharge from the tb. should early monitoring of severely injured trauma patients within the hospital improves discharge temperature, the foundation for two additional research studies will be laid. firstly, the investigators will enter a vanguard phase of this trial and assess if early warming patients can improve morbidity and mortality in this patient population utilizing a multi-centered randomized controlled trial design. this will be further extended to test whether early monitoring can be applied in a pre-hospital setting (i.e. within ambulances and transport vehicles) to improve admission temperatures in the tb.


Eligibility criteria:
inclusion criteria: * patients \>18 years of age * severely injured trauma patients with a revised trauma score (rts) ≤ 11 brought into the shsc tb. exclusion criteria: * patients with blast injuries to the face or severe facial trauma will be excluded. * major burn patients - as they follow a separate care pathway at shsc
safety and efficacy registry of yinyi stent (sery-ii)

Conditions: Coronary Artery Disease

Summary: drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. persistent polymer could be responsible. local delivery of paclitxel from a polymer-free yinyi stent (dalian yinyi biomaterial research and development co.ltd) may prevent these complications.


Eligibility criteria:
inclusion criteria: * age 18-80 years old * both gender * native coronary lesion * narrowing \> 70% * vessel size 2.5-4.0 in diameter exclusion criteria: * without informed consent, * st elevation myocardial infarction within 7 days, * patient with ≤ 70% coronary narrowing at target lesion, * left main lesion, * multivessel narrowing need more than 3 stent implantations, * by-pass graft, * abnormal liver function before randomization, * active hepatitis or muscular disease, * impaired renal function with serum creatinine level \> 3mg/dl, * impaired left ventricular function with lvef \< 30%, * participate in other studies.